42 citations
,
December 2007 in “American Journal of Psychiatry” Finasteride may effectively reduce Tourette's syndrome symptoms and improve life quality.
11 citations
,
January 2020 in “Dermatologica Sinica” Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
September 2025 in “Journal of the American Academy of Dermatology” Ritlecitinib may help treat alopecia areata by protecting hair follicles.
1 citations
,
May 2026 in “Journal of Dermatological Treatment” JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
22 citations
,
March 2017 in “Journal of the Formosan Medical Association” The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.
6 citations
,
July 2025 in “Cancer Medicine” ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.
June 2026 in “Saudi Medical Horizons Journal” JAK inhibitors show promise in treating skin conditions like eczema, hair loss, and vitiligo but need more safety research.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
May 2025 in “JEADV Clinical Practice” Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
January 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Semecarpus anacardium leaf extracts may offer safe, effective cancer treatment alternatives.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
July 2025 in “Journal of Investigative Dermatology” Baricitinib stops hair loss and promotes regrowth in alopecia areata.
December 2025 in “Dermatology The American Medical Journal” JAK inhibitors are effective for long-term management of alopecia areata.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
February 2026 in “Reports — Medical Cases Images and Videos” Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
February 2026 in “Annals of Case Reports” Tofacitinib helped a patient regrow hair after 40 years of total hair loss.
January 2021 in “Our Dermatology Online” Oral tofacitinib successfully treated total body hair loss in one patient.
January 2024 in “Skin Research and Technology” Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.
2 citations
,
January 2025 in “Сибирский научный медицинский журнал” TS-13 effectively stops tumor growth and reduces chemotherapy side effects.
6 citations
,
January 2013 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” A new compound shows promise as a topical treatment for hair loss.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology”
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
15 citations
,
January 2014 in “Medicinal chemistry” Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.
4 citations
,
May 2025 in “Frontiers in Immunology” JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.
June 2021 in “DOAJ (DOAJ: Directory of Open Access Journals)” JAK inhibitors show promise for treating alopecia areata but their effectiveness and safety are still debated.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.